Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
31 January 1997Website:
http://www.cerus.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 22:37:33 GMTDividend
Analysts recommendations
Institutional Ownership
CERS Latest News
Cerus Corporation (NASDAQ:CERS ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayaraman - COO Kevin Green - CFO Conference Call Participants Matthew Park - Cantor Fitzgerald Colin Wells - Stifel Jacob Johnson - Stephens Joshua Jennings - TD Cowan Vidyun Bais - BTIG William Bonello - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Third Quarter 2024 Earnings Conference Call.
Cerus (CERS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2024 financial results will be released on Wednesday, October 30, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit t.
Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.07 per share a year ago.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion (ISBT), taking place in Barcelona, Spain, from June 23 through June 27. Transfusion medicine experts and professionals from around the world attend the ISBT Congress. The following is a list of selected presentations and abstracts of interest for Cerus. All presentation times are listed.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2024. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. For 2024, the focus of this day is on all blood donors, essential for ensuring patients have access to blood transfusion, as well as on efforts to overcome challenges and.
Cerus Corporation (NASDAQ:CERS) will be hosting a conference call to discuss their Q1 2024 results on May 2, 2024 at 4:30 PM ET. The call will feature key company executives including Jessica Hanover, Obi Greenman, Vivek Jayaraman, Kevin Green, and Carol Moore. Analysts participating in the call include Emily Christy, Jacob Johnson, Ross Osborne, and William Bonello. The operator will begin the call shortly. Thank you for joining us.
Cerus Corporation (NASDAQ:CERS ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President & Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to Cerus Corporation Second Quarter 2023 Earnings Conference Call.
Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago.
Cerus (CERS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago.
What type of business is Cerus?
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
What sector is Cerus in?
Cerus is in the Healthcare sector
What industry is Cerus in?
Cerus is in the Medical Devices industry
What country is Cerus from?
Cerus is headquartered in United States
When did Cerus go public?
Cerus initial public offering (IPO) was on 31 January 1997
What is Cerus website?
https://www.cerus.com
Is Cerus in the S&P 500?
No, Cerus is not included in the S&P 500 index
Is Cerus in the NASDAQ 100?
No, Cerus is not included in the NASDAQ 100 index
Is Cerus in the Dow Jones?
No, Cerus is not included in the Dow Jones index
When was Cerus the previous earnings report?
No data
When does Cerus earnings report?
Next earnings report date is not announced yet